We are live on ! Find out more
BRNS

Barinthus Biotherapeutics
BRNS

15 hedge funds and large institutions have $20M invested in Barinthus Biotherapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

15% more funds holding

Funds holding: 13 → 15 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

1.71% less ownership

Funds ownership: 27.37% → 25.66% (-1.7%)

8% less capital invested

Capital invested by funds: $21.6M → $20M (-$1.65M)

Holders
15
Holders Change
+2
Holders Change %
+15.38%
% of All Funds
0.24%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
2
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$53.5K
2
Baird Financial Group
Baird Financial Group
Wisconsin
+$40.3K
3
Citadel Advisors
Citadel Advisors
Florida
+$35.2K
4
UBS Group
UBS Group
Switzerland
+$2.35K
5
TRCT
Tower Research Capital (TRC)
New York
+$289

Top Sellers

Rank Fund Capital Flow
1
LIP
Liontrust Investment Partners
United Kingdom
-$762K
2
Morgan Stanley
Morgan Stanley
New York
-$126K
3
Millennium Management
Millennium Management
New York
-$94K
Name Holding Trade Value Shares
Change 		Change in
Stake
MGIM
1
M&G Investment Management
United Kingdom
$10.4M – – –
AI
2
Alphabet Inc
California
$3.12M – – –
HH
3
HSG Holding
Hong Kong
$2.93M – – –
DF
4
DC Funds
Virginia
$1.32M – – –
BCM
5
BlueCrest Capital Management
Jersey
$1.12M – – –
Baird Financial Group
6
Baird Financial Group
Wisconsin
$404K +$40.3K +17,000 +9%
LIP
7
Liontrust Investment Partners
United Kingdom
$276K -$762K -321,930 -71%
JHU
8
Johns Hopkins University
Maryland
$222K – – –
Renaissance Technologies
9
Renaissance Technologies
New York
$70K +$53.5K +22,600 +198%
IIM
10
Ipswich Investment Management
Massachusetts
$55.8K – – –
Morgan Stanley
11
Morgan Stanley
New York
$31.8K -$126K -53,350 -78%
Citadel Advisors
12
Citadel Advisors
Florida
$30.6K +$35.2K +14,877 New
UBS Group
13
UBS Group
Switzerland
$2.05K +$2.35K +993 New
TRCT
14
Tower Research Capital (TRC)
New York
$251 +$289 +122 New
NECFA
15
New England Capital Financial Advisors
Connecticut
$215 – – –
Millennium Management
16
Millennium Management
New York
– -$94K -41,945 Closed

BRNS Hedge Fund Activity: Q2 2023 in Review

15 of the 6,371 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q2 2023, worth a combined $20M — down 7.6% from $21.6M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new BRNS positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $53.5K. The largest seller was Liontrust Investment Partners, cutting an estimated $762K.

  • 15 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q2 2023, up from 13 in Q1 2023.
  • Funds reported $20M of Barinthus Biotherapeutics stock for Q2 2023, down 7.6% quarter-over-quarter.
  • 3 funds opened new Barinthus Biotherapeutics positions in Q2 2023 and 1 closed out, a net change of +2 holders.
  • The largest Barinthus Biotherapeutics buyer in Q2 2023 was Renaissance Technologies, an estimated $53.5K added.
  • The largest Barinthus Biotherapeutics seller in Q2 2023 was Liontrust Investment Partners, an estimated $762K sold.

Based on aggregated 13F filings for Q2 2023.